Examining the risk factors for trastuzumab-related cardiotoxicity in a predominantly Hispanic South Texas population: A descriptive study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic ...

For individuals with advanced chronic kidney disease (CKD), angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) treatment is associated with a reduced risk for kidney ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls. (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

TCT 150: The Role of Endothelial Shear Stress and Shear Stress Gradient in the Development and Eruption of Coronary Calcified Nodules Receive the the latest news, research, and presentations from ...